191
Views
4
CrossRef citations to date
0
Altmetric
Reviews

Humanized mice for the development and testing of human vaccines

, PhD, , , PhD & , MD PhD
Pages 949-960 | Published online: 08 Aug 2007

Bibliography

  • SHORTMAN K, LIU YJ: Mouse and human dendritic cell subtypes. Nat. Rev. Immunol. (2002) 2:151-161.
  • BRIGL M, BRENNER MB: CD1: antigen presentation and T cell function. Annu. Rev. Immunol. (2004) 22:817-890.
  • CERWENKA A, LANIER LL: Natural killer cells, viruses and cancer. Nat. Rev. Immunol. (2001) 1:41-49.
  • MESTAS J, HUGHES CC: Of mice and not men: differences between mouse and human immunology. J. Immunol. (2004) 172:2731-2738.
  • MOSIER DE, GULIZIA RJ, BAIRD SM, WILSON DB: Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature (1988) 335:256-259.
  • MCCUNE JM: The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 241:1632-1639.
  • KAMEL-REID S, DICK JE: Engraftment of immune-deficient mice with human hematopoietic stem cells. Science (1988) 242:1706-1709.
  • SHULTZ LD, ISHIKAWA F, GREINER DL: Humanized mice in translational biomedical research. Nat. Rev. Immunol. (2007) 7:118-130.
  • SANJEEVI CB: Genes influencing innate and acquired immunity in type 1 diabetes and latent autoimmune diabetes in adults. Ann. NY Acad. Sci. (2006) 1079:67-80.
  • GORONZY JJ, WEYAND CM: Rheumatoid arthritis. Immunol. Rev. (2005) 204:55-73.
  • PRICE P, WITT C, ALLCOCK R et al.: The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases. Immunol. Rev. (1999) 167:257-274.
  • FROHMAN EM: Multiple sclerosis. Med. Clin. North Am. (2003) 87:867-897, viii-ix.
  • TANEJA V, DAVID CS: HLA transgenic mice as humanized mouse models of disease and immunity. J. Clin. Invest. (1998) 101:921-926.
  • TANEJA V, BEHRENS M, MANGALAM A et al.: New humanized HLA-DR4-transgenic mice that mimic the sex bias of rheumatoid arthritis. Arthritis Rheum. (2007) 56:69-78.
  • HAMMER RE, MAIKA SD, RICHARDSON JA, TANG JP, TAUROG JD: Spontaneous inflammatory disease in transgenic rats expressing HLA-B27 and human β2m: an animal model of HLA-B27-associated human disorders. Cell (1990) 63:1099-1112.
  • NABOZNY GH, BAISCH JM, CHENG S et al.: HLA-DQ8 transgenic mice are highly susceptible to collagen-induced arthritis: a novel model for human polyarthritis. J. Exp. Med. (1996) 183:27-37.
  • DAS P, DRESCHER KM, GELUK A et al.: Complementation between specific HLA-DR and HLA-DQ genes in transgenic mice determines susceptibility to experimental autoimmune encephalomyelitis. Hum. Immunol. (2000) 61:279-289.
  • ABRAHAM RS, KUDVA YC, WILSON SB, STROMINGER JL, DAVID CS: Co-expression of HLA DR3 and DQ8 results in the development of spontaneous insulitis and loss of tolerance to GAD65 in transgenic mice. Diabetes (2000) 49:548-554.
  • RAJU R, ZHAN WZ, KARACHUNSKI P et al.: Polymorphism at the HLA-DQ locus determines susceptibility to experimental autoimmune myasthenia gravis. J. Immunol. (1998) 160:4169-4174.
  • PAJOT A: A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice. Eur. J. Immunol. (2004) 34:3060-3069.
  • FUGGER L, MICHIE SA, RULIFSON I, LOCK CB, MCDEVITT GS: Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region β-chain T-cell repertoire and mediates an HLA-DR-restricted immune response. Proc. Natl. Acad. Sci. USA (1994) 91:6151-6155.
  • GELUK A, TANEJA V, VAN MEIJGAARDEN KE et al.: Identification of HLA class II-restricted determinants of Mycobacterium tuberculosis-derived proteins by using HLA-transgenic, class II-deficient mice. Proc. Natl. Acad. Sci. USA (1998) 95:10797-10802.
  • BOTTEN J, ALEXANDER J, PASQUETTO V et al.: Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J. Virol. (2006) 80:8351-8361.
  • MACHLENKIN A, AZRIEL-ROSENFELD R, VOLOVITZ I et al.: Preventive and therapeutic vaccination with PAP-3, a novel human prostate cancer peptide, inhibits carcinoma development in HLA transgenic mice. Cancer Immunol. Immunother. (2007) 56:217-226.
  • OKAZAKI T: Possible therapeutic vaccine strategy against human immunodeficiency virus escape from reverse transcriptase inhibitors studied in HLA-A2 transgenic mice. J. Virol. (2006) 80:10645-10651.
  • PASCOLO S: HLA class I transgenic mice: development, utilization and improvement. Expert Opin. Biol. Ther. (2005) 5:919-938.
  • STREET MD, DOAN T, HERD KA, TINDLE RW: Limitations of HLA-transgenic mice in presentation of HLA-restricted cytotoxic T-cell epitopes from endogenously processed human papillomavirus type 16 E7 protein. Immunology (2002) 106:526-536.
  • BOSMA GC, CUSTER RP, BOSMA MJ: A severe combined immunodeficiency mutation in the mouse. Nature (1983) 301:527-530.
  • TARY-LEHMANN M, SAXON A, LEHMANN PV: The human immune system in hu-PBL-SCID mice. Immunol. Today (1995) 16:529-533.
  • IFVERSEN P, BORREBAECK CA: SCID-Hu-PBL: a model for making human antibodies? Semin. Immunol. (1996) 8:243-248.
  • SANDHU J, SHPITZ B, GALLINGER S, HOZUMI N: Human primary immune response in SCID mice engrafted with human peripheral blood lymphocytes. J. Immunol. (1994) 152:3806-3813.
  • COCCIA MA, BRAMS P: High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells. J. Immunol. (1998) 161:5772-5780.
  • GARCIA S, DADAGLIO G, GOUGEON ML: Limits of the human-PBL-SCID mice model: severe restriction of the Vβ T-cell repertoire of engrafted human T cells. Blood (1997) 89:329-336.
  • SAXON A: Limited B cell repertoire in severe combined immunodeficient mice engrafted with peripheral blood mononuclear cells derived from immunodeficient or normal humans. J. Clin. Invest. (1991) 87:658-665.
  • DUCHOSAL MA, EMING SA, MCCONAHEY PJ, DIXON FJ: Characterization of hu-PBL-SCID mice with high human immunoglobulin serum levels and graft-versus-host disease. Am. J. Pathol. (1992) 141:1097-1113.
  • WILLIAMS SS, UMEMOTO T, KIDA H, REPASKY EA, BANKERT RB: Engraftment of human peripheral blood leukocytes into severe combined immunodeficient mice results in the long term and dynamic production of human xenoreactive antibodies. J. Immunol. (1992) 149:2830-2836.
  • MARTENSSON C, KRISTENSSON K, KALLIOMAKI S, BORREBAECK CA, CARLSSON R: Antigen-specific human immunoglobulin production in SCID mice transplanted with human peripheral lymphocytes is dependent on CD4+ CD45RO+ T cells. Immunology (1994) 83:171-179.
  • BANUELOS SJ, SHULTZ LD, GREINER DL et al.: Rejection of human islets and human HLA-A2.1 transgenic mouse islets by alloreactive human lymphocytes in immunodeficient NOD-scid and NOD-Rag1(null)Prf1(null) mice. Clin. Immunol. (2004) 112:273-283.
  • BANKERT RB, EGILMEZ NK, HESS SD: Human-SCID mouse chimeric models for the evaluation of anti-cancer therapies. Trends Immunol. (2001) 22:386-393.
  • MOSIER DE: Viral pathogenesis in hu-PBL-SCID mice. Semin. Immunol. (1996) 8:255-262.
  • DUCHOSAL MA, MCCONAHEY PJ, ROBINSON CA, DIXON FJ: Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice. J. Exp. Med. (1990) 172:985-988.
  • SAEKI Y: Transfer of multiple sclerosis into severe combined immunodeficiency mice by mononuclear cells from cerebrospinal fluid of the patients. Proc. Natl. Acad. Sci. USA (1992) 89:6157-6161.
  • LAPENTA C: Potent immune response against HIV-1 and protection from virus challenge in hu-PBL-SCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-α. J. Exp. Med. (2003) 198:361-267.
  • VAN KUYK R: Cloned human CD8+ cytotoxic T lymphocytes protect human peripheral blood leukocyte-severe combined immunodeficient mice from HIV-1 infection by an HLA-unrestricted mechanism. J. Immunol. (1994) 153:4826-4833.
  • OKADA M: The development of vaccines against SARS corona virus in mice and SCID-PBL/hu mice. Vaccine (2005) 23:2269-2272.
  • MACCHIARINI F, MANZ MG, PALUCKA AK, SHULTZ LD: Humanized mice: are we there yet? J. Exp. Med. (2005) 202:1307-1311.
  • MOSIER DE, STELL KL, GULIZIA RJ, TORBETT BE, GILMORE GL: Homozygous scid/scid;beige/beige mice have low levels of spontaneous or neonatal T cell-induced B cell generation. J. Exp. Med. (1993) 177:191-194.
  • YACOUB-YOUSSEF H: Engraftment of human T, B and NK cells in CB.17 SCID/beige mice by transfer of human spleen cells. Transpl. Immunol. (2005) 15:157-164.
  • LORBER MI: Human allogeneic vascular rejection after arterial transplantation and peripheral lymphoid reconstitution in severe combined immunodeficient mice. Transplantation (1999) 67:897-903.
  • MARCHEIX B: Multiple human mesenteric arterial grafts from the same donor to study human chronic vascular rejection in humanized SCID/beige mice. J. Heart Lung Transplant. (2006) 25:675-682.
  • MOSIER DE, PICCHIO GR, BAIRD SM, KOBAYASHI R, KIPPS TJ: Epstein–Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes. Cancer Res. (1992) 52:s5552-s5553.
  • RONCAROLO MG, CARBALLIDO JM, ROULEAU M, NAMIKAWA R, DE VRIES JE: Human T-and B-cell functions in SCID-hu mice. Semin. Immunol. (1996) 8:207-213.
  • VANDEKERCKHOVE BA: Human Ig production and isotype switching in severe combined immunodeficient-human mice. J. Immunol. (1993) 151:128-137.
  • NAMIKAWA R, WEILBAECHER KN, KANESHIMA H, YEE EJ, MCCUNE JM: Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. (1990) 172:1055-1063.
  • KYOIZUMI S: Implantation and maintenance of functional human bone marrow in SCID-hu mice. Blood (1992) 79:1704-1711.
  • VANDEKERCKHOVE BA, KROWKA JF, MCCUNE JM et al.: Clonal analysis of the peripheral T cell compartment of the SCID-hu mouse. J. Immunol. (1991) 146:4173-4179.
  • CARBALLIDO JM, NAMIKAWA R, CARBALLIDO-PERRIG N et al.: Generation of primary antigen-specific human T- and B-cell responses in immunocompetent SCID-hu mice. Nat. Med. (2000) 6:103-106.
  • ROULEAU M, NAMIKAWA R, ANTONENKO S, CARBALLIDO-PERRIG N, RONCAROLO MG: Antigen-specific cytotoxic T cells mediate human fetal pancreas allograft rejection in SCID-hu mice. J. Immunol. (1996) 157:5710-5720.
  • MCCUNE J: The SCID-Hu mouse: a small animal model for HIV infection and pathogenesis. Annu. Rev. Immunol. (1991) 9:399-429.
  • MELKUS MW: Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. (2006) 12:1316-1322.
  • SUN Z: Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J. Exp. Med. (2007) 204:705-714.
  • CHICHA L: Human adaptive immune system Rag2-/-γ(c)-/- mice. Ann. NY Acad. Sci. (2005) 1044:236-243.
  • LEGRAND N, WEIJER K, SPITS H: Experimental models to study development and function of the human immune system in vivo. J. Immunol. (2006) 176:2053-2058.
  • VORMOOR J: Immature human cord blood progenitors engraft and proliferate to high levels in severe combined immunodeficient mice. Blood (1994) 83:2489-2497.
  • CASHMAN JD: Kinetic evidence of the regeneration of multilineage hematopoiesis from primitive cells in normal human bone marrow transplanted into immunodeficient mice. Blood (1997) 89:4307-4316.
  • LAPIDOT T: Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science (1992) 255:1137-1141.
  • SHULTZ LD: Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. (1995) 154:180-191.
  • YAHATA T: Functional human T lymphocyte development from cord blood CD34+ cells in nonobese diabetic/Shi-scid, IL-2 receptor γ null mice. J. Immunol. (2002) 169:204-209.
  • ITO M: NOD/SCID/γ(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 100:3175-3182.
  • SHULTZ LD: Human lymphoid and myeloid cell development in NOD/LtSz-scid IL2R γ null mice engrafted with mobilized human hemopoietic stem cells. J. Immunol. (2005) 174:6477-6489.
  • ISHIKAWA F: Development of functional human blood and immune systems in NOD/SCID/IL2 receptor γ chain(null) mice. Blood (2005) 106:1565-1573.
  • TRAGGIAI E: Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 304:104-107.
  • BANCHEREAU J, Steinman RM: Dendritic cells and the control of immunity. Nature (1998) 392:245-252.
  • PALUCKA AK: Human dendritic cell subsets in NOD/SCID mice engrafted with CD34+ hematopoietic progenitors. Blood (2003) 102:3302-3310.
  • WATANABE S: Hematopoietic stem cell-engrafted NOD/SCID/IL2Rγ null mice develop human lymphoid system and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood (2007) 109:212-218.
  • HIRAMATSU H: Complete reconstitution of human lymphocytes from cord blood CD34+ cells using the NOD/SCID/γc null mice model. Blood (2003) 102:873-880.
  • BAENZIGER S: Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γc-/- mice. Proc. Natl. Acad. Sci. USA (2006) 103:15951-15956.
  • LAN P, TONOMURA N, SHIMIZU A, WANG S, YANG YG: Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood (2006) 108:487-492.
  • BENTE DA, MELKUS MW, GARCIA JV, RICO-HESSE R: Dengue fever in humanized NOD/SCID mice. J. Virol. (2005) 79:13797-13799.
  • ISLAS-OHLMAYER M, PADGETT-THOMAS A, DOMIATI-SAAD R et al: Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein–Barr virus. J. Virol. (2004) 78:13891-13900.
  • ASPORD C, PEDROZA-GONZALEZ A, GALLEGOS M et al.: Breast cancer instructs dendritic cells to prime interleukin 13-secreting CD4+ T cells that facilitate tumor development. J. Exp. Med. (2007) 204:1037-1047.
  • GREGERSEN JW, HOLMES S, FUGGER L: Humanized animal models for autoimmune diseases. Tissue Antigens (2004) 63:383-394.
  • GIMENO R: Monitoring the effect of gene silencing by RNA interference in human CD34+ cells injected into newborn RAG2-/-γc-/- mice: functional inactivation of p53 in developing T cells. Blood (2004) 104:3886-3893.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.